11 terminated. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 11 |
| Phase 2 | 4 | Terminated 4 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients GEM00220 - Septic Shock | Phase 1 | Terminated | Northern Therapeutics | 11 | 2021-08-11 | 2024-04-16 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
| The Val-CARD Trial Sodium Valproate - Cardiac Valve Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Terminated | University of Leicester | 45 | 2018-11-06 | 2026-08-17 |
| Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Stress-dose Hydrocortisone plus Vitamin C, isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo - Septic Shock | Phase 1 / Phase 2 | Terminated | University of Athens | 26 | 2018-09-06 | 2024-12-19 |
| A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2) Valproic Acid, Isotonic saline solution - Shock,Hemorrhagic, Trauma | Phase 1 | Terminated | Dr. Hasan Alam | 1 | 2016-11-01 | 2017-11-06 |
| Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock 25% Albumin, Placebo - Shock, Septic | Phase 1 | Terminated | Alexander Flannery, 859-323-4011 | 11 | 2016-03-01 | 2019-04-04 |
| Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis BMS-936559, Placebo - Severe Sepsis, Septic Shock | Phase 1 | Terminated | Bristol-Myers Squibb | 35 | 2015-12-02 | 2017-09-15 |
| Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period Dobutamine - Shock | Phase 1 / Phase 2 | Terminated | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | 15 | 2014-05-30 | 2017-10-17 |
| L-Carnitine Administration in Early Sepsis L-Carnitine, Normal Saline - Septic Shock | Phase 1 | Terminated | Wake Forest University Health Sciences | 31 | 2010-09-01 | 2022-04-22 |
| Enteral Glutamine Supplementation for the Patient With Major Torso Trauma Glutamine - Trauma, Critical Illness | Phase 1 | Terminated | The University of Texas Health Science Center, Houston | 20 | 2005-06-01 | 2010-04-23 |
| The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis IgM-enriched Intravenous Immunoglobulins, Human Albumin - Polyneuropathies | Phase 1 | Terminated | Medical University of Vienna | 38 | 2004-12-01 | 2013-06-04 |
Shock, Septic (5) · Sepsis (4) · Critical Illness (2) · Multiple Organ Failure (2) · Wounds and Injuries (2) · Acute Lung Injury (1) · COVID-19 (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Heart Valve Diseases (1) · Infections (1) · Inflammation (1) · Lung Diseases (1)
Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Systemic Inflammatory Response Syndrome (7) · Infections (6) · Inflammation (6) · Disease Attributes (2) · Sepsis (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Coronaviridae Infections (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Heart Diseases (1)
Valproic Acid (2) · Albumins (1) · Ascorbic Acid (1) · BMS-936559 (1) · Carnitine (1) · Dobutamine (1) · Glutamine (1) · Immunoglobulins, Intravenous (1) · Placebo Effect (1) · Saline Solution (1) · Serum Albumin, Human (1)
Alexander Flannery, 859-323-4011 (1) · Bristol-Myers Squibb (1) · Dr. Hasan Alam (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz (1) · Medical University of Vienna (1) · Northern Therapeutics (1) · Rapa Therapeutics LLC (1) · The University of Texas Health Science Center, Houston (1) · University of Athens (1) · University of Leicester (1) · Wake Forest University Health Sciences (1)
United States (6) · Austria (1) · Canada (1) · Greece (1) · Spain (1) · United Kingdom (1)
Adelina Pellicer, MD PhD (1) · Alan E Jones, MD (1) · Alexander H. Flannery, Pharm.D. (1) · Anastasia Kotanidou, MD, PhD (1) · Christian Madl, MD (1) · Daniel Fowler, M.D. (1) · Gavin Murphy, MD (1) · Hasan Alam, MD (1) · Heike Rabe, MD PhD (1) · Margaret M McQuiggan, MS, RD, CNSD (1) · Marius Roman, MD (1) · Spyros D Mentzelopoulos, MD, PhD (1) · Spyros G Zakynthinos, MD. PhD (1)
PMID 24088271, PMID 26825368, PMID 30747773
2018 (1), M01RR002558 (1)